Tag Archives: risk

Conference Recap – 2011 ACRP Global Conference and Exhibition

Posted on 26 May 2011 by Ask-Cato.com Contributor

The 2011 Association of Clinical Research Professionals (ACRP) Global Conference and Exhibition was held on 30 April – 03 May 2011 in Seattle, WA. The conference hosted 2,000 registrants including physicians, nurses, pharmacists, clinical research coordinators, clinical research associates, and other clinical research professionals. Continue reading →

Posted in Clinical Trials, Conferences and Meetings | Tagged , , , , , , , , , , , , , , , , , , , , , , | Comments Off

Conference Recap – BayBio 2011

Posted on 11 May 2011 by Ask-Cato.com Contributor

The BayBio Annual Conference 2011 was held on 20-21 April 2011 in Burlingame, CA.  The event was attended by more than 1,000 San Francisco Bay Area biotech and life sciences professionals from over 400 companies. This year’s conference focused on … Continue reading →

Posted in Conferences and Meetings, Venture Capital | Tagged , , , , , , , , , , , , , , , , , | Comments Off

New FDA Guidances – March 2011

Posted on 8 April 2011 by Ask-Cato.com Contributor

Each month, Cato Research Regulatory Scientist Cathy Anderson compiles a list of the notable guidance documents released by the FDA.  Here’s a summary of the guidances released in March 2011 (most links go directly to PDF documents). Postmarketing Studies and … Continue reading →

Posted in Clinical Trials, FDA, Industry News, Regulatory Strategy | Tagged , , , , , , , , | Comments Off

Free Webinar – Past, Present and Future of REMS: Can We Mitigate With Restraint?

Posted on 22 June 2010 by Evan Richardson

Join Cato Research for a free educational webinar on Thursday, 24 June 2010 at 2:00 PM ET.  The webinar, titled Past, Present and Future of REMS: Can We Mitigate With Restraint?, will be presented by Jack Snyder, M.D., J.D., Ph.D., … Continue reading →

Posted in Webinars | Tagged , , | 1 Comment

An FDA Perspective on Risk/Benefit

Posted on 27 May 2010 by Leo DiNapoli

If a man is alive, there is always danger that he may die, though the danger must be allowed to be less in proportion as he is dead-and-alive to begin with. A man sits as many risks as he runs. … Continue reading →

Posted in FDA | Tagged , , , , , , | Comments Off